Evidence map›Paper›PMID 34819124›Full record

ArticleOrphanet journal of rare diseases2021

Impacts and Burden of Niemann pick Type-C: a patient and caregiver perspective.

Eugen Mengel, Marc C Patterson, Michael Chladek, Christina Guldberg, Christine Í Dali, Tara Symonds, Lucy Lloyd-Price, Toni Mathieson, Joslyn Crowe, Claire Burbridge

Open access · goldAbstract read
In one paragraph

Article in Orphanet journal of rare diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 3 countries.

Eugen MengelInstitute of Clinical Science for LSD, SphinCS GmbH, Hochheim, Germany.
Marc C PattersonMayo Clinic Children's Center, Rochester, MN, USA.
Michael ChladekClinical Outcomes Solutions, Chicago, IL, USA.
Christina GuldbergOrphazyme A/S, Copenhagen, Denmark.
Christine Í DaliOrphazyme A/S, Copenhagen, Denmark.
Tara SymondsClinical Outcomes Solutions, Folkestone, Kent, UK.
Lucy Lloyd-PriceClinical Outcomes Solutions, Folkestone, Kent, UK.
Toni MathiesonNiemann-Pick UK, Washington, Tyne and Wear, UK.
Joslyn CroweNational Niemann-Pick Disease Foundation, Fort Atkinson, WI, USA.
Claire BurbridgeClinical Outcomes Solutions, Folkestone, Kent, UK. claire.burbridge@clinoutsolutions.com.ORCID 0000-0003-0117-7169
Orphazyme (Denmark) · DKAtkins (United States) · USHealth Economics and Outcomes Research (United Kingdom) · GBHealth Outcomes Solutions (United States) · USMayo Clinic · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNiemann-Pick disease type C (NPC) is a debilitating condition that impacts patients' and caregivers' quality of life (QOL) and reduces the patient's life expectancy. Since there is little qualitative research from the perspective of patients and family caregivers, this study explored the impact of NPC on patients' and caregivers' daily lives to understand the burden of disease.

resultsA survey of caregivers for patients with NPC and adult patients with NPC (n = 49; patient age: 13 months-65 years) assessed NPC severity, importance of NPC symptoms, and how symptoms impacted patients' and caregivers' activities of daily living (ADLs) and health-related QOL (HRQOL). Follow-up interviews with a subset of survey participants (n = 28) explored the ranking of NPC symptom importance and impact on ADLs and HRQOL. Findings indicated that the most important manifestations of NPC were ambulation, swallowing, speech, fine motor skills, and cognition, which were those that had the most significant impact on ADLs and HRQOL. A wide range of ADLs were affected by NPC, mainly eating/drinking and the ability to perform daily tasks, including self-care, communicating, participating in school or work, and moving indoors as well as outside the home. Along with these impacts, there was an increased risk of experiencing dangerous or life-threatening situations leading to loss of patient independence and additional caregiver burden, often requiring changes in lifestyle such as giving up work. All aspects of patients' and caregivers' HRQOL were affected. Participants reported feelings of social isolation, loss of enjoyment in activities (patients), and feelings of sadness or worry (caregivers).

conclusionsAmbulation, swallowing, speech, fine motor skills, and cognition are important manifestations of NPC. ADLs and HRQOL were impaired in the majority of patients as well as their caregivers. The findings were independent of current age, age of onset of symptoms, and level of NPC disease-related disability; however, the impact increased at higher levels of disease disability. Knowing the impact of NPC on patients and caregivers is important for understanding the lived experience of NPC and for identifying potential areas of support.

Indexed as

CaregiversNiemann-Pick Disease, Type CActivities of Daily LivingAdultHumansInfantQuality of LifeSurveys and QuestionnairesIllness burdenImpactsNiemann pick Type-CNPCQualitative

Identifiers

PMID34819124
PMCPMC8611877
OpenAlexW3127945104

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.